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The only thing that is certain about death is that upon it, no
life remains, and that the risk of death during a person’s
lifetime is 1. These facts cannot be disputed; however,
assessments over how much life has been prematurely lost
upon death have led to polarised views. The impact of
COVID-19 is drawing increased attention on how we
approach putting a value on the life prematurely lost by
death (Appleby 2020; Hanlon et al. 2020; Kirigia and
Muthuri 2020).
Years of life lost to premature mortality (YLL) is a
frequently used population health metric, originating back
to the 1940s (Haenszel 1950). The idea is appealingly
simple—instead of merely counting the number of deaths,
each death is weighted as a function of the age at death,
reflecting the common appreciation that deaths at young
ages are more severe than deaths at advanced ages. How-
ever, there is no single unique way to operationalise the
concept, reflecting the reality that YLL can never be
observed. Indeed, the estimation of YLL requires
assumptions on the counterfactual, parallel world that did
not happen—how long would the person have lived had
they not have died?
The debate around this normative assumption is largely
centred on the choice of mortality risk that residual values
for age-conditional life expectancy in YLL calculations are
based on. Should they be based upon mortality risks that
are country-specific, or risks that are external to the pop-
ulation studied, and are chosen to be aspirationally low? It
may seem rational to use national life tables, reflecting the
country-specific mortality risks, until we estimate residual
life expectancy for sub-national units. This highlights that
particular groups, such as those with a socioeconomic
disadvantage, have very different mortality risks. Take
Singapore, which has the highest life expectancy in the
world (Institute for Health Metrics and Evaluation. GBD
results tool. Global Health Data Exchange 2020). The
mortality risk in Singapore is not representative for that in
Scotland—for instance, the former country has a residual
life expectancy for females aged 75 that is 3.67 years
higher than the latter. However, looking at differences
between the most and least deprived areas for this demo-
graphic in Scotland also yields a large disparity, of
2.91 years (National Records of Scotland 2016). This
raises the issue of why people are comfortable with the idea
that life could be valued differently between countries, but
are then uncomfortable with the idea of assigning different
values of residual life expectancy on the basis of an indi-
vidual’s sub-national location. Using a national life
table furthermore creates a paradox by which increased
mortality risks, of for instance the COVID-19 pandemic,
could cause life expectancy to go down, which could result
in a contradictory reduction in estimates of YLL
(McCartney et al. 2020).
A second major point of discussion is whether YLL
should be corrected for comorbidities of the deceased
(Hanlon et al. 2020; Cassini et al. 2019). This is particu-
larly the case for COVID-19, which frequently causes
death in the old and frail, and those with underlying
chronic conditions. Some thus argue that valuing the death
of a 90-year-old nursing home resident with advanced
cardiac decompensation using the national life expectancy
for 90-year olds would ‘‘overestimate’’ YLL due to
COVID-19.
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What these discussions make clear is the importance of
transparency in documenting the exact method used to
calculate YLL. Since YLL cannot be observed, they can
only be estimated, and obviously, the choice of counter-
factual will have a major influence on the resulting esti-
mates. Conversely, YLL can never be ‘‘overestimated’’ or
‘‘underestimated’’, since there is no ‘‘true’’ value of YLL.
The paradoxes and pitfalls described here can be cir-
cumvented by using a ‘‘standard’’ life table, based on
aspirational mortality risks. Although these mortality risks
may be lower than are currently observed in countries, they
have many comparative and ethical advantages. This
approach ensures that we do not accept a level of mortality
risk merely because we are used to it, as to do this means
we lose focus of the factors and environment that are
responsible for it. Importantly, assessments on the value of
human life are equal between, and within, countries. This is
important as it means we are upfront about the extent of
national and global inequalities, and the World Health
Organisation’s goal of health for all and what that means
(World Health Organisation 2020). Finally, through
assuming a counterfactual based on a world free of disease,
standard life tables allow measuring the impact of different
diseases at the same level, which is essential for compar-
ative studies such as the Global Burden of Disease study
(GBD 2017 DALYs and HALE Collaborators 2018).
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